Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan

Abstract

pan as well as in many other Westernizing countries. 1 Most of the disease activity in UC patients is mild to moderate, and 5-aminosalicylic acid (5-ASA) has been the most basic drug administered to mild and moderate UC patients. Multiple studies have demonstrated the efficacy of 5-ASA for preventing relapse as well as inducing remission. 2,3 However, most of patients experience disease relapse, even when they continuously take 5-ASA. Once relapse occurs, patients need to take other medications, such as steroids, other immune modifying drugs or biologics. 4 Therefore, optimizing the use of 5-ASA is needed in order to ensure a better course in UC pa

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis

“…4b). Concomitant use of proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) is considered to affect the lysis of pH-dependent 5-ASA preparations [6][7][8]. In this study, the insoluble excretion rate was 6% lower in the patients who used PPIs or H2RAs in combination with 5-ASA.…”

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α

“…In addition, the most commonly used 5-ASA-based drug, mesalamine (brand names include Asacol, Salofalk, Mezavant, and Pentasa, Ferring, Saint-Prex, Switzerland) has been developed in various newer formulations [ 11 ]. To reach the colon mucosa without being absorbed in the stomach and small intestine, 5-ASA must be bound to a drug-delivery system or prodrug [ 12 , 13 ]. Asacol, consisting of 5-ASA coated with Eudragit S100 (Daewoong, Seoul, Korea), which is a polymethacrylate copolymer that only dissolves at pH ≥ 7, targets the terminal ileum and colon [ 14 ].…”